From: How to schedule VEGF and PD-1 inhibitors in combination cancer therapy?
Notation | Description | Value used | References |
---|---|---|---|
d D | Death rate of DCs | 0.1 day−1 | [59] |
\(d_{T_{1}}\) | Death rate of CD 4+ T cells | 0.197day−1 | [59] |
\(d_{T_{8}}\) | Death rate of CD 8+ T cells | 0.18day−1 | [59] |
\(d_{T_{r}}\) | Death rate of Tregs | 0.2day−1 | [61] |
d E | Death rate of endothelial cells | 0.69 day−1 | [43] |
d C | Death rate of tumor cells | 0.17 day−1 | [59] |
\(d_{I_{12}}\) | Degradation rate of IL-12 | 1.38 day−1 | [59] |
\(d_{I_{2}}\) | Degradation rate of IL-2 | 2.376 day−1 | [59] |
\(d_{T_{\beta }}\) | Degradation rate of TGF-β | 499.066 day−1 | [15] |
d W | Take-up rate of oxygen by cells | 1.04 day−1 | Estimated |
d G | Degradation rate of VEGF | 12.6 day−1 | [43] |
d A | Degradation rate of anti-PD-L1 | 0.34 day−1 | Estimated |
η 1 | Killing rate of cancer cells by T1 | 30.19 cm3/g·day | Estimated |
η 8 | Killing rate of cancer cells by T8 | 60.375 cm3/g·day | Estimated |
d B | Degradation rate of anti-VEGF | 0.17 day−1 | Estimated |
μ PA | Blocking rate of PD-1 by anti-PD-1 | 4.33×107cm3/g·day | Estimated |
μ AP | Degradation rate of anti-PD-1 in blocking PD-1 | 4.33×107cm3/g·day | Estimated |
μ GB | Blocking rate of VEGF by anti-VEGF | 2.19×107cm3/g·day | Estimated |
μ BG | Degradation rate of anti-VEGF in blocking VEGF | 1.31×108cm3/g·day | Estimated |
K D | Half-saturation of CD 4+ T cells | 4×10−4g/cm3 | [15] |
\(K_{T_{1}}\) | Half-saturation of CD 4+ T cells | 2×10−3g/cm3 | [15] |
\(K_{T_{8}}\) | Half-saturation of CD 8+ T cells | 1×10−3g/cm3 | [15] |
\(K_{T_{r}}\) | Half-saturation of Tregs | 5×10−4g/cm3 | [15] |
K E | Half-saturation of endothelial cells | 2.5×10−3g/cm3 | [43] |
K C | Half-saturation of tumor cells | 0.4 g/cm3 | [15] |
\(K_{I_{12}}\) | Half-saturation of IL-12 | 8×10−10g/cm3 | [15] |
\(K_{I_{2}}\) | Half-saturation of IL-2 | 2.37×10−11g/cm3 | [15] |
\(K_{T_{\beta }}\) | Half-saturation of TGF-β | 2.68×10−13g/cm3 | [15] |
K W | Half-saturation of oxygen | 1.69×10−4g/cm3 | [43] |
K G | Half-saturation of VGEF | 7×10−8g/cm3 | [43] |
\(K_{TT_{r}}\) | Inhibition of function of T cells by Tregs | 5×10−4g/cm3 | [15] |
\(K^{\prime }_{TQ}\) | Inhibition of function of T cells by PD-1-PD-L1 | 1.68×10−18g2/cm6 | Estimated |
K PB | Block of anti-PD-1 perfusion by anti-VEGF (mice) | 1×10−8g/cm3 | Estimated |
K PB | Block of anti-PD-1 perfusion by anti-VEGF (humans) | 1×10−9g/cm3 | Estimated |
D 0 | Density of immature DCs | 2×10−5 g/ cm3 | [59] |
T 10 | Density of naive CD 4+ T cells | 4×10−4 g/ cm3 | [15] |
T 80 | Density of naive CD 8+ T cells | 2×10−4 g/ cm3 | [15] |
E M | Carrying capacity of endothelial cells | 5×10−3 g/ cm3 | [43] |
C M | Carrying capacity of cancer cells | 0.8 g/ cm3 | [59] |
G 0 | Threshold VEGF concentration | 3.65×10−10 g/ cm3 | [43] |
\(\hat T_{1}\) | Density of CD 4+ T cells from lymph node | 4×10−3 g/ cm3 | [15] |
\(\hat T_{8}\) | Density of CD 8+ T cells from lymph node | 2×10−3 g/ cm3 | [15] |
\(\hat E\) | Density of endothelial cells from outside of tumor | 5×10−3 g/ cm3 | Estimated |
W ∗ | Hypoxia threshold oxygen level | 1.69×10−4 g/ cm3 | [44] |
W 0 | Normal threshold oxygen level | 4.65×10−4 g/ cm3 | [44] |